UDJ1 Stock Chart & Stats
€0.12
€0.00(0.00%)
At close: 4:00 PM EDT
€0.12
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €6.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€849.44K
Enterprise Value€2.64
Total Cash (Recent Filing)€949.09K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,197,223
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp TTM revenue rebound indicates that BNB Plus has regained substantial top-line activity after the prior period. If maintained, this larger revenue base could improve operating leverage and support a path toward better earnings, although profitability has not yet followed.
Low Financial LeverageMinimal debt reduces interest burden and refinancing exposure, giving BNB Plus more financial flexibility than a similarly unprofitable company with significant leverage. The stronger capital base may provide room to pursue restructuring or growth initiatives if cash consumption is reduced.
Investor-linked Board ExpansionThe new directors deepen ties with investor-affiliated digital infrastructure entities and add participants connected to the company’s strategic review and financings. This could strengthen access to capital-market expertise and align governance more closely with its evolving digital infrastructure strategy.
Bears Say
Extreme UnprofitabilityThe revenue rebound has not translated into earnings power, as operating and net losses remain exceptionally large relative to sales. Such weak margins suggest the current cost base is materially outsized for the business and make a durable recovery dependent on substantial operating improvement.
Severe Cash ConsumptionPersistent negative operating and free cash flow means BNB Plus is consuming significant cash while its business remains unprofitable. Continued funding needs could constrain strategic execution and lead to additional financing requirements unless cash generation improves materially.
Nasdaq Delisting And Reduced LiquidityThe move from Nasdaq to OTCQB is a structural deterioration in the company’s market access, with the article expecting a less liquid market. Reduced trading liquidity can make future capital raising harder and increase the financing burden for a cash-consuming business.
BNB Plus News
UDJ1 FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was €0.01 and its highest was €6.00 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is €849.44K.
When is BNB Plus’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BNB Plus’s earnings last quarter?
Currently, no data Available
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 6,197,223 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in DE:UDJ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―